Today’s Research Reports on Trending Tickers: Puma Biotechnology and Corcept Therapeutics

U.S. markets finished mostly lower on Thursday, as broader market was dragged lower by weak performance from the industrial and energy sector matched with ongoing trade tension between U.S. and China. The Dow Jones Industrial Average decreased 0.29 percent to close at 25,509.23, while the S&P 500 Index fell 0.14 percent to close at 2,853.58. The Nasdaq Composite Index climbed 0.04 percent to close at 7,891.78, posting its 8th consecutive daily gain.

“Things are looking good in the U.S. in terms of earnings and data, but things aren’t as rosy if you look to China, emerging markets or Europe. Weakness in those regions could eventually become a headwind for the U.S.,” said Suzanne Hutchins, senior portfolio manager of Dreyfus Global Real Return Fund. “The U.S. market seems to be shrugging off any sort of risk right now, since the S&P 500 is near a record and volatility is low. We think that’s wrong, as trade would become quite challenging for the global economy,” she added.

RDI Initiates Coverage on:

Puma Biotechnology, Inc.

Corcept Therapeutics Incorporated

Puma Biotechnology’s stock moved 0.72% higher Thursday, to close the day at $48.65. The stock recorded a trading volume of 1,241,552 shares, which was above its three months average volume of 922,817 shares. In the last year, Puma Biotechnology’s shares have traded in a range of 46.55 – 136.90. The share price has gained 4.51% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $53.27 is below its 200-day moving average of $60.98. Shares of Puma Biotechnology have fallen roughly 15.98 percent in the past month and are down 50.78 percent year-to-date.

Access RDI’s Puma Biotechnology, Inc. Research Report at:

On Thursday, shares of Corcept Therapeutics recorded a trading volume of 1,109,294 shares, which was below the three months average volume of 1,267,634 shares. The stock ended the day 0.71% lower at $13.98. The share price has fallen 46.15% from its 52 week high with a 52 week trading range of 12.50 – 25.96. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $14.45 is below its 200-day moving average of $16.94. Shares of the company are trading at a Price to Earnings ratio of 12.37. Shares of Corcept Therapeutics have fallen roughly 9.46 percent in the past month and are down 22.59 percent year-to-date.

Access RDI’s Corcept Therapeutics Incorporated Research Report at:

Our Actionable Research on Puma Biotechnology, Inc. (NASDAQ:PBYI) and Corcept Therapeutics Incorporated (NASDAQ:CORT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:



[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.